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Abstract 
Recently co-crystals have emerged as a potential approach to improve the solubility, 
dissolution, and bioavailability of active pharmaceutical ingredients (API).  Often co-crystal 
formation is studied in the development stage in order to solve an issue (with solid form or 
formulation) or to expand intellectual property.  However, co-crystals may have the potential of 
enhancing the developability of a poorly soluble lead candidate in the discovery stage.  In this 
study, piroxicam, a BCS (Biopharmaceutical Classification System) Class II compound with low 
solubility, was chosen as a model drug to explore this possibility.  The solution phase reaction 
crystallization method was chosen over slow evaporation as a way to make co-crystals because it 
can produce pure co-crystals that can be scaled by simply using the solubility data of the parent 
and coformer.  A screen of carboxylic acid coformers yielded six piroxicam co-crystals which 
were characterized.  Co-crystal aqueous solubility was measured and models were used to 
calculate co-crystal pH dependent solubility.  Intrinsic dissolution rates of the co-crystals were 
measured in biorelevant media.  Co-crystals were found to be more soluble and the dissolution 
rates were lower than the parent.  Piroxicam oral exposure in rat from the co-crystals was 
determined and was similar to free piroxicam. 
 
 
 
 
 
 
iv 
 
Acknowledgements 
I would like to thank my on site research advisor, Dr. Deborah Galinis, for her guidance 
and encouragement throughout this research project.  I am very grateful for the support and 
flexibility afforded to me from Cephalon and Teva Pharmaceuticals to pursue this masters 
program as well as the enthusiasm from my directors Dr. Mehran Yazdanian and Dr. Rob 
McKean, and vice president Dr. Craig Heacock.  I am appreciative of the University of Kansas 
Pharmaceutical Chemistry Department for offering this distance masters program and am 
especially thankful for my KU advisor, Dr. Valentino Stella, for his guidance and scientific 
discussions.  I am extremely grateful to Dr. Nair Rodríguez-Hornedo for personally sharing her 
expertise with me on solution phase reaction crystallization and co-crystal solubility.  Much of 
this work would not have been possible without the help from several of my colleagues including 
Dr. Laurent Courvoisier, Steve Bierlmaier, and Curtis Haltiwanger for their help with solid state 
analysis techniques, Dr. Lisa Aimone for sharing her in-vivo knowledge and suggestions, and 
Damaris Rolon-Steele and Kelli Zeigler for performing in-vivo pharmacokinetic studies.  Lastly, 
I would like to thank my husband and family for their love, support, and patience while I pursued 
this degree.    
 
 
 
v 
 
Table of Contents 
Chapter 1.  Introduction 
Pharmaceutical Interest in Co-crystals      1 
Co-crystal Synthesis Methods       3 
Piroxicam as a Model Compound       4 
References          6 
 
Chapter 2.  Piroxicam Co-crystals by Slow Evaporation 
 Introduction          8 
 Experimental          9 
 Results and Discussion                  14 
 Conclusions                    19 
 References                    20  
 
Chapter 3.  Piroxicam Co-crystals by Reaction Crystallization 
 Introduction                    21 
 Experimental                    23 
 Results and Discussion                  26 
 Conclusions                    33 
 References                    34 
 
Chapter 4.  Co-crystal Solubility 
 Introduction                    35 
 Experimental                    36 
 Results and Discussion                  38 
 Conclusions                    45 
 References                    46 
 
Chapter 5.  Intrinsic Dissolution and Pharmacokinetics  
 Introduction                    47 
 Experimental                    48 
 Results and Discussion                  50 
 Conclusions                    60 
 References                    61 
 
Chapter 6.  Final Conclusions and Future Considerations              63 
Chapter 7.  Appendix 
 Slow Evaporation Solid State Data                 65 
 Reaction Crystallization Solid State Data                83 
 Co-crystal Solubility                   93 
 Intrinsic Dissolution                   99 
 Pharmacokinetic Data                 119
1 
 
CHAPTER 1.  Introduction 
 
 
Purpose of the Research Performed  
The purpose of the research covered in this thesis was to explore the use of co-crystal 
formation to alter the physical/chemical properties of the non-steroidal drug, piroxicam, in order 
to improve drug solubility, dissolution, and bioavailability. 
 
Pharmaceutical Interest in Co-crystals 
 In the past decade, drug candidates have evolved toward compounds with increasing 
molecular weight and lipophilicity often resulting in poorly water soluble drugs.
1
 This has 
remained a key issue for pharmaceutical candidates with drugs often failing in development due 
to their low aqueous solubility.
2
 Limited solubility often causes poor and variable oral absorption 
because the dissolution rate or solubility is insufficient to completely dissolve the drug in the 
gastrointestinal tract.
3    
Recently pharmaceutical co-crystals have emerged as a promising solid state technique to 
improve API (active pharmaceutical ingredient) properties such as solubility, dissolution rate, 
bioavailability, and stability.
4-8 
 A review by Schultheiss and Newman on pharmaceutical co-
crystals and their physiochemical properties lists several definitions of a co-crystal such as a 
solid molecular complex at room temperature containing a neutral, ionic, or zwitterionic 
molecule of the API and one or more complementary molecules (coformers) including excipients 
(non-toxic ingredients) or other APIs.
8
  However, the FDA guidance that was recently released 
on pharmaceutical co-crystals specifies that the co-crystal components exist in their neutral states 
2 
 
and interact via non-ionic interactions, as opposed to ionic interactions, which would classify this 
crystalline solid as a salt form.
9   
The API and coformer can interact through hydrogen bonding, 
π-stacking, or van der Waals forces.
10
  In theory, all types of drug molecules have the capability 
to form co-crystals; therefore, co-crystals have advantages over traditional solid-state 
modification techniques (e.g., salts, solvates, hydrates, and polymorphs).  For example, co-
crystals provide an alternative for APIs that are unable to form salts due to lack of ionization 
moieties.  
Pharmaceutical co-crystals provide a means to increase API solubility, dissolution rate, 
and bioavailability.   For example, the aqueous solubility of seven carbemazepine co-crystals 
measured by Good and Rodiguez-Hornedo was approximately 2 to 152 times greater than the 
solubility of the stable carbamazepine dihydrate form.
11
  In a study by Stanton et. al., AMG 517 
co-crystals paired with cinnamic acid, benzoic acid, cinnamamide, and benzamide gave 
significant increases in dissolution rate and oral exposure compared to the free base form.
12 
 Jung 
et. al. created indomethacin-saccharin co-crystals that produced higher in vitro dissolution rates 
at pH 1.2 and 7.4 as well as higher bioavailability in dogs than indomethacin.
13   
However, this 
improvement was not significantly different from the marketed product, Indomee
®
.  In another 
study, an increase in bioavailability in dogs was also demonstrated using glutaric acid co-
crystals.
14 
Co-crystals have also been used to overcome API stability issues such as polymorphism 
and hydroscopicity.
7-8   
An example where co-crystals were used to reduce hydroscopicity was 
with caffeine.  It is well known that caffeine is subject to hydrate formation.
1
   Caffeine-
dicarboxylic acid co-crystals resisted hydrate formation, even when prepared from the hydrated 
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drug form.
15
  Furthermore, caffeine co-crystals with oxalic acid were non-hydroscopic and stable 
over several weeks when maintained at 43-98% relative humidity.
15
  In a similar case,  Trask et. 
al. found that theophylline co-crystals with oxalic, malonic, maleic, and glutaric acid did not 
hydrate at high relative humidity.
16
  A carbamazepine/saccharin co-crystal created by Hickey et. 
al. is a case where co-crystallization reduced the incidence of polymorphism compared to pure 
carbamazepine, which has four known polymorphs and several solvates.
17  
The physical and 
chemical stability as well as the oral bioavailability of the carbamazepine co-crystal was proven 
to be quantitatively similar to the pure drug in the marketed product, Tegretol
®
.   
 
Co-crystal Synthesis Methods 
It is relatively straight forward for the medicinal chemist to create a salt form based on 
the pKa value(s) of a lead molecule and that of the intended acid or base used to form the salt.
7 
 
However, several different methods have been reported to screen and make co-crystals including 
wet cogrinding, sonic slurry, and slow evaporation.
2, 5, 18
  These studies are generally carried out 
in ternary systems (API, coformer, and solvent) and phase diagrams are generated that describe 
the conditions for thermodynamic stability and provide insight into the experimental conditions 
that may lead to co-crystal formation.
18  
With these methods, solvent or solvent mixtures with 
similar solubilities for reactants are chosen and stoichiometric amounts of the reactants are used.  
Often times, slow evaporation experiments are performed in a high throughput screening mode 
in which small quantities of co-crystals are identified in a 96 well plate.
19
  Slow evaporation 
accounts for approximately 40% of the co-crystallization techniques appearing in the literature.
20 
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 Reaction crystallization is another strategy used to identify and generate co-crystals.  This 
method is also based on the solubilities of the reactants; however, nonstoichiometric reactant 
solution concentrations are used.
18
 Co-crystals are generated via supersaturation with respect to 
the co-crystal in a liquid phase that is ideally saturated or undersaturated with respect to the 
reactants.
21, 22
  In other words, a saturated solution of the reactants is made with the intention of 
creating an environment where the co-crystal form is supersaturated and precipitates out of 
solution.  
 
These methods afford a variety of options but also make it difficult to decide which 
approach will be the most successful.  Ideally the method used will identify and produce co-
crystals relatively quickly so that the co-crystals can be tested to determine if they have an 
advantage over the API itself.  It is also important that the co-crystal synthesis method chosen is 
reproducible and scalable in order to produce the significant amount of material required for 
solubility, intrinsic dissolution, and in vivo studies.  Finally and most importantly, the method 
has to yield pure co-crystal material so that accurate conclusions can be made when the co-
crystals are tested.   
 
Piroxicam as a Model Compound 
Piroxicam was chosen as a model compound to explore co-crystal formation in this 
research because it is a Biopharmaceutics Classification System (BCS) Class II compound, 
which by definition has low solubility and high permeability.  It is a nonsteroidal anti-
inflammatory drug used in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
23
 
Solubility and permeability are the fundamental properties determining the bioavailability of an 
5 
 
orally active drug; therefore, poor oral absorption is often an issue for BCS Class II drug.
24
  Co-
crystals of Class II compounds have been shown to increase bioavailability in some cases.
10
  
When dosed orally, it takes more than two hours for piroxicam to reach maximum concentration 
which indicates the oral exposure is limited by solubility.
25-27
  Piroxicam (Figure 1.1) is a 
zwitterionic molecule with two pKa values (pKa1 = 1.8, pKa2 = 5.1).
28
   
 
 
Figure 1.1:  Structure of piroxicam. 
Co-crystals of piroxicam have been previously reported.
29, 30
  In a small scale screening 
experiment, fifty co-crystals containing piroxicam and a carboxylic acid coformer were 
identified.
29
 A study of saccharin as a salt former also yielded a piroxicam-saccharin co-crystal.
30
 
Based on these reports of piroxicam co-crystals, several coformers were chosen for this research 
in order to explore different co-crystal synthesis strategies and to improve solubility and 
potential oral bioavailability in an early drug development setting.  Piroxicam co-crystal 
solubility, dissolution rate, and oral bioavailability were also investigated. 
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CHAPTER 2.  Piroxicam Co-crystals by Slow Evaporation 
 
Purpose of the Research Performed  
The purpose of the research performed in this chapter was to explore the feasibility of 
creating scale-up batches of co-crystals by slow evaporation. 
 
Introduction 
 Childs and Hardcastle performed an extensive small scale co-crystal screen with 
piroxicam and 23 carboxylic acids using solution based and solid-state grinding methods.
1
 The 
solution based screen was done in a 96-well format with stoichiometric amounts of piroxicam 
and the carboxylic acids and various solvent mixtures.  These solutions were allowed to slowly 
evaporate to dryness at room temperature.  Solid-state grinding screening methods were also 
utilized to study physical mixtures of piroxicam and 20 carboxylic acids in 1:1 and 1:2 
API/coformer combinations.  Raman spectroscopy and X-ray powder diffraction (XRPD) were 
used to characterize the solids.  Single piroxicam co-crystals were also grown by slow 
evaporation with 10 carboxylic guest compounds and four different solvent combinations.  From 
these experiments, single crystal data was reported for nine piroxicam/carboxylic acid co-
crystals.   
Five of these acid/solvent combinations were used in this thesis in order to determine the 
feasibility of growing co-crystals by slow evaporation on a larger scale (50 mg – 2 g).  The 
structures of the coformers used as well as the ratio of piroxicam to coformer are listed in Table 
2.1.  The solids were characterized by XRPD, differential scanning calorimetry (DSC), and 
9 
 
thermal gravimetric analysis (TGA).  XRPD patterns were compared to the single crystal data 
reported by Childs and Hardcastle
1
 to determine whether or not the solid was in fact a co-crystal.  
XRPD and DSC data were also obtained for piroxicam, each acid, and physical mixtures of 
piroxicam and each acid.  The solid XRPD patterns were also compared to other known forms of 
piroxicam.
2
  
Table 2.1:  Coformer structures and co-crystal ratio.  
Coformer Structure Piroxicam / Coformer Ratio 
 
1-hydroxy, 2-Naphthoic acid 
 
 
1:1 
 
Malonic acid 
 
 
1:1 and 2:1 
 
 
4-hydroxy Benzoic Acid 
 
 
 
1:1 
 
Succinic Acid 
 
 
1:1 and 2:1 
 
Benzoic Acid 
 
 
1:1 
 
 
Experimental 
 
The materials listed in this chapter as well as the XRPD, DSC, and thermogravimetric analysis 
methods were used throughout the entirety of this research.    
10 
 
Materials 
Piroxicam was obtained from 3B Pharmachem International Co. Ltd. (China).  Gentisic 
acid was obtained from MP Biomedicals (Solon, OH).  Saccharin was purchased from Spectrum 
Chemicals (New Brunswick, NJ).  Benzoic acid, fumaric acid, maleic acid, malonic acid, 
tetrahydrofuran, and 2,2,2, trifluoroethanol were purchased from Alfa Aesar (Lancashire, UK).  
4-hydroxy benzoic acid was obtained from TCI America (Portland, OR).  Salicylic acid and 
monobasic potassium phosphate were purchased from J.T. Baker (Phillipsburg, NJ).  Sodium 
chloride, 1-hydroxy 2-naphthoic acid, alprenolol, and mandelic acid was obtained from Sigma-
Aldrich (St. Louis, MO).  Succinic acid and tetrahydrofuran were purchased from EMD 
Chemicals (Cincinnati, OH).  Water, 0.1% trifluoroacetic acid in water, acetonitrile, isopropanol, 
and methanol were all HPLC grade and purchased from J.T. Baker (Phillipsburg, NJ).   
X-ray Powder Diffraction (XRPD) 
Powder XRD patterns were recorded on a PANalytical X Pert Pro diffractometer 
equipped with an X celerator detector using Cu K radiation at 45 kV and 40 mA. K1 radiation 
is obtained with a highly oriented crystal (Ge111) incident beam monochromator.  A 10 mm 
beam mask, and fixed (1/4) divergence and anti-scatter (1/8) slits were inserted on the incident 
beam side. A fixed 5 mm receiving slit was inserted on the diffracted beam side. The X-ray 
powder pattern scan was collected from ca. 2 to 40° 2θ with a 0.0080° step size and 96.06 sec 
counting time which resulted in a scan rate of approximately 0.5°/min. The sample was spread 
on a silicon zero background (ZBG) plate for the measurement. The sample was rotated at 15 
revolutions/min on a PANalytical PW3065/12 Spinner. 
 
11 
 
Differential Scanning Calorimetry (DSC) 
Thermal curves were acquired using a Perkin-Elmer Sapphire DSC unit equipped with an 
autosampler running Pyris software version 6.0 calibrated with Indium prior to analysis. Solid 
samples of 1-10 mg were weighed into 20 µL aluminum sample pans with pin hole lids. The 
DSC cell was then purged with nitrogen and the temperature heated from 0 to 375°C at 10°C / 
min.  Indium (Tm = 156.6ºC; ∆HFUS = 28.45 J g
−1
) was used for calibration. 
Thermogravimetric Analysis (TGA)  
Thermal curves were acquired using a Perkin-Elmer Pyris 1 TGA unit running Pyris 
software version 6.0 calibrated with alumel (95% nickel, 2% manganese, 2% aluminum and 1% 
silicon), nickel and calcium oxalate monohydrate. TGA samples between 1-5 mg were monitored 
for percent weight loss as heated from 25 to 250°C at 10°C/min in a furnace purged with Helium 
at ca. 50 mL/min.  
High Performance Liquid Chromatography (HPLC) 
The purity of the co-crystal components was assessed by HPLC.  The HPLC-UV 
instrument used was an Agilent 1200 series (Palo Alto, CA) equipped with a UV diode array 
detector (Agilent Technologies, Palo Alto, CA) and contained an Agilent Zorbax Bonus RP 4.6 x 
150mm, 3.5 micron column.  Concentrations were determined using a gradient method from 5% 
solvent B (acetonitrile containing 0.1% trifluoroacetic acid) in solvent A (water containing 0.1% 
trifluoroacetic acid) to 95% solvent B in solvent A in 25 minutes, isocratic at 100% solvent B for 
1.5 minutes, then equilibrate for 5 minutes at 5% solvent B in solvent A.  The flow rate was 1 
mL/min.  Calibration curve standards were prepared in methanol at 1, 10, 100, and 250 µg/mL.  
12 
 
The wavelengths of absorbance monitored for piroxicam and 4-hydroxy benzoic acid were 325 
and 254 nm respectively.  All other acids were monitored at 210 or 220 nm. 
Co-crystal Slow Evaporation Method 
 Crystals were grown by slow evaporation at room temperature using the methods and 
solvents described by Childs and Hardcastle.
1
  The amount of piroxicam and coformer required 
for the desired co-crystal yield (e.g. 50 mg, 100 mg, etc.) was calculated based on the molecular 
weight of the co-crystal.  Piroxicam and coformers were weighed into a glass vial and solvent 
was then added until all the solid was dissolved.  The vials were sealed with paraffin wax paper 
and a small hole was punched in the paper and then set to evaporate.  Table 2.2 lists the 
experimental details for each co-crystal. 
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Table 2.2:  Experimental parameters for co-crystal slow evaporation. 
Co-Crystal 
MW 
(g/mole) 
Batch 
Scale 
(mg) 
Amount 
Piroxicam 
Used (mg) 
Amount 
Coformer 
Used (mg) 
Total 
Solvent 
Volume 
(mL) 
Evaporation 
Time 
(weeks) 
Solvent 
1:1 
Piroxicam/ 
1-hydroxy 2-
Naphthoic 
Acid 
519.52 
50 31.44 18.74 15 6  
 
2:1 
Tetrahydrofuran/ 
Isopropanol 
500 323.1 177.27 30 3  
1000 639.61 363.39 75 5  
1:1 
Piroxicam/ 
Malonic Acid 
662.69 
50 25.14 7.91 16 7  
1:1 
Trifluoroethanol/ 
Acetonitrile 
500 259.5 78.5 50 6  
2000 1007 314.22 140 5  
2:1 
Piroxicam/ 
Malonic Acid 
766.77 
500 500.49 78.71 80 6 
1:1 
Trifluoroethanol/ 
Acetonitrile 
1000 1000 158.28 160 6 
2000 1999 313.9 300 6 
1:1 
Piroxicam/ 
4-hydroxy 
Benzoic Acid 
469.46 
 
50 
35.5 14.8 16 6  
 
1:1 Methanol/ 
Acetonitrile  
500 
359 150 90 3  
1:1 
Piroxicam/ 
Succinic 
Acid 
449.43 
100 84.12 30.43 30 4  
2:1 
Tetrahydrofuran/ 
Isopropanol 
500 424.65 151.25 105 4 
1000 849.27 302.62 180 5 
2:1 
Piroxicam/ 
Succinic 
Acid 
780.786 
200 84.75 15.27 15 6  
2:1 
Tetrahydrofuran/ 
Isopropanol 
1000 422.84 147.63 45 3  
2000 1697.3 301.17 120 5  
1:1 
Piroxicam/ 
Benzoic Acid 
453.46 
50 36.4 13.4 16 6  
 
1:1 Methanol/ 
Acetonitrile 
500 366 135.69 90 3  
2000 1451 543.31 250 4  
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Results and Discussion 
 In the piroxicam co-crystal study by Childs
1
, more detailed experimental synthesis 
methods were given for the nine single crystal co-crystals reported.  Out of these nine, the five 
piroxicam/acid/solvent sets used in this thesis were chosen because did not require 
heating/cooling or produce a mixture of co-crystal forms.  Co-crystal XRPD results for the 
batches of co-crystals made in this research could then be directly compared to the single crystal 
data reported by Childs.     
  A total of seven slow evaporation experiments with piroxicam and five carboxylic acid 
coformers in either 1:1 or 2:1 piroxicam/acid stoichiometric ratios were performed.  A summary 
of the data collected for each batch of co-crystal is listed in Table 2.3.  Coformer melting points 
are also included in this table as a reference.  The melting point of the piroxicam material used 
was 207ºC.  The remaining solids after evaporation were analyzed by HPLC to assess the purity 
of piroxicam and the coformers.  No chemical degradation was observed.  A stability study of 
piroxicam in all the solvent combinations proved piroxicam to be stable at room temperature for 
at least 42 days. XRPD patterns and DSC thermograms not shown in this chapter can be found in 
the appendix. 
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Table 2.3:  Summary of co-crystal recovery and characterization. 
Co-Crystal 
Batch 
Scale 
(mg) 
Pure Co-crystal? 
Weight Loss by 
TGA 
(%) 
Co-crystal MP 
by DSC 
(ºC) 
Coformer MP 
by DSC 
(ºC) 
1:1 
Piroxicam/ 
1-hydroxy 2-
Naphthoic 
Acid 
50 Maybe <1 195 
200.8 500 Maybe 1.6 195 
1000 Maybe <1 188, 196 
1:1 
Piroxicam/ 
Malonic Acid 
50 No 7.2 145, 162, 191 
95.5, 139.6 500 No 11.0 
85, 140, 143, 
160, 199 
2000 No 15.8 88, 139, 142 
2:1 
Piroxicam/ 
Malonic Acid 
500 No 16.9 110, 160, 204 
95.5, 139.6 1000 No 8.6 157, 203 
2000 No 10.4 87, 160, 205 
1:1 
Piroxicam/ 
4-hydroxy 
Benzoic Acid 
 
50 
No <1 186, 197 
217.9 
 
500 
No 1.4 188, 197 
1:1 
Piroxicam/ 
Succinic 
Acid 
100 No <1 156, 170, 180 
193.3 500 No 1.3 155, 170, 180 
1000 No 1.3 155, 170, 177 
2:1 
Piroxicam/ 
Succinic 
Acid 
200 No <1 170, 180 
193.3 1000 No <1 47, 81, 170, 188 
2000 No <1 
155, 170, 204, 
234, 245 
1:1 
Piroxicam/ 
Benzoic Acid 
50 No 13.1 
122, 141, 168, 
198 
124.7 500 No 18.3 135, 168, 198 
2000 No 10.2 118, 169 
  
 1:1 Piroxicam/1-hydroxy 2-Naphthoic Acid.  XRPD results (Figure 2.1) were 
reproducible for the 50 mg, 500 mg and 1 g scales made.  The XRPD data mostly matched the 
single crystal data in the literature with the exception of a few peaks, which could be small 
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impurities or other crystalline forms.
  
The co-crystals had very little weight loss (< 1 %) when 
heated up to 250°C and DSC (Figure 2.2) gave one endotherm at 195°C for the 50 and 500 mg 
batches suggesting that the material was mostly pure.  A small endotherm at 188°C was observed 
for the 1 g batch.  Based on these results, it is possible that the material is a co-crystal. 
 
Figure 2.1:  XRPD patterns for 1:1 piroxicam/1-hydroxy 2-naphthoic acid and starting materials. 
5 10 15 20 25 30 35 40 
2Theta (°) 
0 
2500 
10000 
22500 
Intensity (counts) 
500 mg scale 
1 g scale 
50 mg scale 
Literature Single Crystal Data 
1:1 Piroxicam / 1-Hydroxy 2-Naphthoic Acid 
1-Hydroxy 2-Naphthoic Acid  
Starting Material 
Piroxicam Starting Material 
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Figure 2.2:  DSC thermograms for 1:1 piroxicam/1-hydroxy 2-naphthoic acid and starting  
materials. 
 
1:1 and 2:1 Piroxicam/Malonic Acid.  The 1:1 crystals had a few peaks that matched 
the literature single crystal data as well as peaks that matched the malonic acid starting material.  
Water and excess malonic acid were observed in the DSC data.  A broad endotherm at 160°C 
matched the DSC results for the physical mixture.  This endotherm could also represent a 
solvate, which would correlate with the large weight loss by TGA (7-15%).  Due to the excess 
malonic acid observed in the DSC data, an attempt was made to make a 2:1 co-crystal.  XRPD 
patterns of 1:1 and 2:1 piroxicam/malonic acid crystals did not compare.  The 1 g and 2 g scales 
for the 2:1 crystals produced large crystals so a crystal was submitted for single crystal analysis.  
Single crystal data proved the crystal to be piroxicam monohydrate and not a co-crystal.  The 
XRPD pattern also correlated with the malonic acid starting materials.  DSC data had multiple 
1 g scale 
50 & 500 mg scale 
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endotherms suggesting water and piroxicam.  Like the 1:1 crystals, the 2:1 also had a broad 
endotherm at 160°C.  About 10-17% weight loss was observed.  From this data it was concluded 
that the 2:1 crystals were not co-crystals and most likely a mixture of piroxicam monohydrate, 
piroxicam, and malonic acid.  The 1:1 crystals appear to be a mixture of co-crystal and malonic 
acid. 
1:1 Piroxicam/4-hydroxy Benzoic Acid:  XRPD results for the 50 mg and 500 mg 1:1 
piroxicam/4-hydroxy benzoic acid crystals were reproducible.  Only a few peaks matched the 
literature single crystal data.  Some of the peaks matched the physical mixture pattern.  DSC 
results had one split endotherm with peaks at 187 and 197°C.  There was very little weight loss 
by TGA.  It is possible that the crystals could be a mixture of co-crystals along with the starting 
materials.       
1:1 and 2:1 Piroxicam/Succinic Acid:  Results for the 1:1 and 2:1 piroxicam/succinic 
acid crystals were confusing.  The 2:1 XRPD patterns did not correlate with the literature single 
crystal data.  The 1:1 and 2:1 patterns were very similar with the exception of a few peaks.  Both 
patterns also had a few peaks that compared with the starting materials.  There were multiple 
endotherms in the DSC data for the crystals.  The DSC data for the 1:1 crystals were 
reproducible for all the batches made.  However, the 2:1 DSC results were not reproducible, with 
the number of endotherms increasing as the scale increased.  The largest endotherm, which was 
present in all of the 1:1 and 2:1 crystals, was at 170°C.  In all of the DSC data, the endotherms 
were sharp peaks which suggests, along with the small weight loss by TGA, that no solvates 
were present.  Overall, there appeared to be multiple substances in the crystals which may or 
may not include co-crystals.   
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1:1 Piroxicam/Benzoic Acid:  The XRPD patterns for all three scales were not 
consistent.  Some of the peaks from each batch matched the literature single crystal data; 
however, many also compared with the physical mixture patterns as well.  The 50 and 500 mg 
DSC data was similar with endotherms at 168 and 198ºC.  The 2 gram scale had an endotherm at 
168ºC but not at 198ºC.  All three scales had endotherms within the 118-140ºC region which 
could correspond to the melt of benzoic acid (melting point at 124ºC).  This theory was also 
supported by the weight loss (10-18%) observed within this temperature region.  It is possible 
that the endotherm at 168ºC could correspond to a co-crystal.  Based on these results, the crystals 
were most likely a mixture of the reactants and possibly some co-crystal material. 
 
Conclusions 
 Out of seven slow evaporation experiments with five carboxylic acid coformers, only the 
1:1 piroxicam/1-hydroxy, 2-napthoic acid crystals appeared to be co-crystals.  All of the other 
crystals produced were physical mixtures of the reactants that may or may not have also 
contained co-crystals.  The Childs reference did not report the concentrations of piroxicam and 
coformer used as well the solution volume and the exact rate of evaporation.
1
  It is possible that 
the scale-up batches did not contain the ideal ternary system of API, coformer, and solvent to 
make the co-crystal form.
 3
   
 While the slow evaporation method works well for identifying co-crystals on a small 
scale, it does not appear to be ideal for scale-up without further method development.  The long 
evaporation time required for large batches of co-crystals is not practical to identify and test new 
API forms.  Obtaining a pure batch of co-crystals was also a major issue for most, if not all, of 
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the slow evaporation experiments conducted.  Without a significant amount of pure material, co-
crystal performance cannot be accurately tested in dissolution, solubility, and in vivo studies.   
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CHAPTER 3.  Piroxicam Co-crystals by Reaction Crystallization 
 
Purpose of the Research Performed  
The purpose of the research performed in this chapter was to investigate co-crystal 
formation by reaction crystallization and to determine if this method was applicable for making 
small and large scale batches of co-crystals.   
 
Introduction 
 Preliminary attempts to create large scale batches of co-crystals by slow evaporation 
proved unsuccessful.  The reactions were difficult to control and produced a mixture of products 
containing little, if any, co-crystal.  Therefore, this method was abandoned in favor of a less time 
consuming and more controlled technique to create co-crystals.   
The mechanisms of the reaction co-crystallization method have been extensively studied 
by Rodríguez-Hornedo and Nehm et. al. using carbamazepine/nicotinamide co-crystals as a 
model.
1, 2
  These experiments are performed by adding reactant B to a saturated or close to 
saturated solution of reactant A, thus supersaturating the solution with respect to co-crystal AB.
3
  
The idea being that once the solution is supersaturated with co-crystal, pure co-crystal will 
precipitate out of solution.  The solubilities of the reactants are used to determine the 
concentration regions required to potentially form a co-crystal, rather than the stoichiometry of 
the co-crystal.
4
  It should be noted that these techniques were explored as early as the 1950’s by 
Higuchi and coworkers.
5-7
  However, his work was more focused on improving the aqueous 
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solubility of poorly soluble compounds via solution complexation and less on the insoluble 
complexes that formed.    
The advantages of the reaction crystallization method are that it can be used in a high 
throughput mode to screen for co-crystals, it is transferable to larger scale co-crystallization 
processes, it affords co-crystal formation at ambient temperature, and can produce pure co-
crystals.
1
  Childs et. al. used reaction crystallization as a screening strategy to identify 11 
carbamezipine co-crystal forms with nine carboxylic acid coformers.
8
  In a study by Li et. al., 
reaction crystallization was used to scale up glutaric acid co-crystals that were originally 
identified in a small scale screen using co-grinding methods.
9
  Co-crystals formed via reaction 
crystallization are often visibly observed quickly.  Reddy et. al. observed co-crystallization of 
gabapentin with several carboxylic acids within minutes.
10
  Carbamezipine co-crystals with 
malonic acid, glutaric acid, saccharin, oxalic acid, succinic acid, and salicylic acid have also 
been reported using this technique.
11 
Piroxicam carboxylic acid coformers explored by Childs et. al.
12
 including benzoic acid, 
salicylic acid, 4-hydroxy benzoic acid, malonic acid, mandelic acid, succinic acid, gentisic acid, 
fumaric acid, and maleic acid were used in this research to study the  reaction crystallization 
method.  Saccharin was also chosen as a coformer to try with this method because a piroxicam 
co-crystal with saccharin has also been reported in the literature.
13
  Piroxicam and coformer 
solubilities in several solvents were measured to determine co-crystal experimental parameters.  
Co-crystals were characterized by XRPD, DSC, TGA, and HPLC. 
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Experimental 
Solubility of Piroxicam and Coformers in Organic Solvents 
Equilibrium solubility of piroxicam and acid coformers in various organic solvents 
(Table 3.2) was determined at room temperature by shaking samples with excess solid overnight 
on an orbital shaker (Lab-Line Instruments, Melrose Park, IL).  Samples were then filtered using 
a 0.45 µm polyvinylidene fluoride membrane (Whatman, Piscataway, NJ).  If necessary, samples 
were diluted in methanol prior to analysis.  Saturated solution concentrations were determined by 
high performance liquid chromatography (HPLC).  The HPLC-UV instrument used was an 
Agilent 1200 series (Palo Alto, CA) equipped with a UV diode array detector (Agilent 
Technologies, Palo Alto, CA) and contained an Agilent Zorbax Bonus RP 4.6 x 150mm 3.5 
micron column.  Concentrations were determined using a gradient method from 5% solvent B 
(acetonitrile containing 0.1% trifluoroacetic acid) to 95% solvent B in 25 minutes, isocratic at 
100% solvent B for 1.5 minutes, then equilibrate for 5 minutes at 5% solvent B.  Solvent A was 
water containing 0.1% trifluoroacetic acid.  The flow rate was 1 mL/min.  Calibration curve 
standards were prepared in methanol at 1, 10, 100, and 250 µg/mL.  The wavelengths of 
absorbance monitored for piroxicam and 4-hydroxy benzoic acid were 325 and 254 nm 
respectively.  All other acids were monitored at 210 or 220 nm. 
Piroxicam Co-crystal Synthesis 
Table 3.1 lists the coformers and solvents tried using the reaction crystallization method.  
For co-crystals that were successful, the experimental parameters (also summarized in Table 3.4) 
are as follows: Benzoic acid, gentisic acid, salicylic acid, 4-hydroxy benzoic acid, and saccharin 
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co-crystals were made in 2,2,2 trifluoroethanol. Approximately 80 – 500 mg of piroxicam was 
added to 1 – 8  mL of presaturated solutions of  benzoic acid, salicylic acid, and 4-hydroxy 
benzoic acid coformers.  The amount of piroxicam added was based on its solubility limit in 
2,2,2 trifluoroethanol (Table 3.2).  Solutions were shaken on an orbital shaker.  Benzoic acid and 
salicylic acid co-crystals were observed within minutes.  4-hydroxy benzoic acid co-crystals 
were apparent after three days.  Gentisic acid and saccharin co-crystals were made by suspending 
200 – 450 mg of the acids in 6 – 12 mL of presaturated piroxicam solutions and shaken over 
night.  Succinic acid co-crystals were made by adding approximately 90 mg of piroxicam to 3 
mL of a saturated succinic acid solution in 2:1 tetrahydrofuran (THF) / 2-propanol (IPA).  The 
solution was shaken overnight.  Succinic acid co-crystals were observed after 2 – 3 hours.  Co-
crystals were collected by vacuum filtration to remove excess solvent and dried in a hood. Co-
crystals were characterized by XRPD, DSC, and TGA.  The piroxicam/acid co-crystal ratio was 
determined by HPLC.  Approximately the same ratios of piroxicam and coformer concentrations 
were used for scale up batches.   
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Table 3.1:  Coformers and solvents tried using reaction crystallization. 
Carboxylic Acid Structure Solvent 
Co-Crystal 
Apparent? 
Benzoic Acid 
 
Trifluoroethanol Yes 
Mandelic Acid 
 
Trifluoroethanol No 
Malonic Acid 
 
Trifluoroethanol 
1:1 THF/IPA 
2:1 THF/IPA 
No 
No 
No 
Salicylic Acid 
 
Trifluoroethanol Yes 
Maleic Acid 
 
Trifluoroethanol No 
Fumaric Acid 
 
Trifluoroethanol 
1:1 TFE/MeOH 
2:1 TFE/MeOH 
1:1 THF/IPA 
2:1 THF/IPA 
No 
No 
No 
No 
No 
Succinic Acid 
 
Trifluoroethanol 
1:1 THF/IPA 
2:1 THF/IPA 
No 
Yes 
Yes 
4-hydroxy Benzoic 
Acid 
 
Trifluoroethanol Yes 
Gentisic Acid 
 
Trifluoroethanol Yes 
Saccharin 
 
Trifluoroethanol Yes 
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Results and Discussion 
Based on a small library of solubility data generated for piroxicam in organic solvents 
(Table 3.2), trifluoroethanol was chosen as the preferred solvent to screen for co-crystals because 
it had the highest piroxicam solubility (100 mg/mL).  High piroxicam solubility was thought to 
be desirable because the aim was to produce a high yield of co-crystal using a minimal amount 
of solvent (1-10 mL).  The solubilities of the co-crystal coformers in the solvents used are listed 
in Table 3.3.    
 
Table 3.2:  Piroxicam solubility in organic solvents. 
Solvent Piroxicam Solubility (mg/mL) 
Trifluoroethanol (TFE) 100 
Tetrahydrofuran (THF) 51 
Methanol (MeOH) 2.3 
Acetonitrile (ACN) 8.3 
Isopropanol (IPA) 1 
1:1 TFE/MeOH 6.1 
1:1 TFE/ACN 11.8 
2:1 TFE/MeOH 9.1 
1:1 THF/IPA 17.5 
2:1 THF/IPA 29.3 
 
Table 3.3:  Coformer solubilities in solvents used to screen and make co-crystals. 
Coformer TFE 
1:1 
TFE/MeOH 
2:1 
TFE/MeOH 
1:1 
THF/IPA 
2:1 
THF/IPA 
Benzoic Acid 35 - - - - 
Mandelic Acid 84 - - - - 
Salicylic Acid 11 - - - - 
Malonic Acid 38 - - 460 490 
Maleic Acid 43 - - - - 
Fumaric Acid 0.2 4.7 2.3 74 80 
Succinic Acid 6.3 - - 121 112 
4-hydroxy Benzoic Acid 3.0 - - - - 
Gentisic Acid 3.3 - - - - 
*ND = Not Determined 
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In the screening experiments, saturated solutions of the least soluble component 
(coformer) were made, filtered, and then the more soluble component (piroxicam) was added in 
an amount just under its solubility limit.  The goal was to not have any excess piroxicam or acid 
in the starting solutions that could be confused as a co-crystal in the initial screening 
experiments.  Furthermore, by not exceeding the solubility limits of the components, the co-
crystal that precipitated out of solution was pure.  Solution concentrations were monitored by 
HPLC throughout the crystallization process to evaluate whether the solid observed appeared to 
be a complex of the reactants (co-crystal).  The solid precipitate was also collected and analyzed 
by HPLC to determine the stoichiometry of the complex.  If the solid appeared to be a co-crystal 
(i.e. had a 1:1 or 2:1 stoichiometry) based the HPLC results, it was further characterized by 
XRPD, DSC, and TGA.       
A summary of the piroxicam and coformer concentrations used to make the co-crystals as 
well as the solution scale, yield, and stoichiometry of the co-crystals are listed in Table 3.4.  Co-
crystal molecular weight and thermal properties are in Table 3.5.  Co-crystal formation was 
successful in trifluoroethanol with all of the aromatic acids.  Succinic acid was the only aliphatic 
acid that formed a co-crystal with piroxicam and it only formed in 1:1 and 2:1 THF/IPA.  Both 
the 1:1 and 2:1 THF/IPA solutions gave the same co-crystal form.  The 2:1 THF/IPA solution 
had a higher co-crystal yield because it had greater piroxicam solubility; therefore, this solvent 
was used to make the scale-up batches.  All co-crystals formed a 1:1 complex with the exception 
of succinic acid, which produced a 2:1 piroxicam/succinic acid co-crystal.  XRPD patterns 
(Figure 3.1) for the co-crystals confirmed unique crystalline forms compared to the starting 
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materials and other known piroxicam forms.
14
  XRPD and thermal data not presented in this 
chapter can be found in the appendix. 
Crystals for the 4-hydroxy benzoic acid co-crystal were large enough to generate single 
crystal X-ray data (Figure 3.2).  It appears as if the co-crystal is comprised of piroxicam in the 
zwitterionic form.  The phenolic hydroxyl group on 4-hydroxy benzoic acid forms a hydrogen 
bond to the enolate oxygen.  The carboxylic acid forms a hydrogen bond to the sulfonyl group on 
piroxicam as well as accepts a hydrogen bond from a protonated pyridine on a neighboring 
piroxicam molecule.  These results are identical to single crystal data previously generated by 
Childs et. al.
12
  The benzoic acid and succinic acid co-crystal XRPD patterns also compare with 
single crystal data previously reported.
12
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Table 3.4:  Co-crystal experimental parameters, yield, and thermal properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coformer 
(Co-crystal 
Abbreviation) 
Solution 
Scale 
(mL) 
Coformer
a
  or 
Piroxicam
b
 
Solution 
Concentration 
(mg/mL) 
Coformer
a
 
or 
Piroxicam
b
 
Added 
(mg) 
Recovery 
(mg) 
Yield 
(%) 
Piroxicam/
Coformer 
Ratio by 
HPLC 
Benzoic Acid 
(PBA) 
1 35
a
 70
b
 60 63 
1:1 
11 35
a
 1020
 b
 1064 76 
Salicylic Acid 
(PSA) 
8 11
a
 500
 b
 155 52 
1:1 
45 11
a
 3200
 b
 1350 80 
4-hydroxy 
Benzoic Acid 
(P4hBA) 
3 3
a
 250
 b
 15 49 
1:1 
200 3
a
 15500
 b
 1480 73 
Saccharin 
(PSacc) 
10 73
b
 447
a
 741 65 
1:1 
12 85
b
 450
a
 960 76 
Gentisic Acid 
(PGA) 
6 83
b
 200
a
 353 56 1:1 
Succinic Acid 
(PSucA) 
5 112
a
 93
 b
 50 46 
2:1 
11 112
a
 343
 b
 164 41 
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Table 3.5:  Co-crystal molecular weight and thermal properties. 
Co-Crystal 
Co-crystal 
MW (g/mole) 
Solution 
Scale (mL) 
Weight Loss 
by TGA (%) 
Co-crystal 
Melting 
Point (ºC) 
Coformer 
Melting 
Point (ºC) 
PBA 453.46 
1 25* 170 
122 
11 <1 170 
PSA 469.46 
8 <1 191 
159 
45 <1 190 
P4hBA 469.46 
3 <1 200 
215 
200 <1 200 
PSacc 514.53 
10 <1 225 
231 
12 <1 225 
PGA 485.46 6 <1 208 205 
PSucA 780.78 
5 <1 172 
193 
11 1.36 170 
*Melt of benzoic acid 
 
 
Figure 3.1:  Co-crystal XRPD patterns. 
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Figure 3.2:  1:1 Piroxicam/4-hydroxy benzoic acid single crystal structure. 
 
Coformers with low solubility required a higher solution volume to produce the desired 
amount of co-crystal.  This was observed for the P4hBA co-crystal, where the solubility limit of 
4-hydroxy benzoic acid in trifluoroethanol was only 3 mg/mL.  The scale up batch required 200 
mL of saturated 4-hydroxy benzoic acid and 15.5 g of piroxicam to yield only 1.5 g of co-crystal 
thus leaving a large amount of unreacted piroxicam.  This was also an issue in the original 
screening experiments for the PGA co-crystals, where excess piroxicam left in the solution 
produced confounding co-crystal stoichiometry when the co-crystals were analyzed by HPLC 
(Table 3.4).  The formation of the piroxicam gentisic acid co-crystals produced a “paste-like” 
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solution which was difficult to filter off the excess solution.  The unreacted piroxicam solution 
that was not completely removed from the co-crystals by filtration resulted in excess piroxicam 
in the co-crystals.  To overcome this issue, the PGA co-crystal scale-up batch (Table 3.3) was 
made by suspending the least soluble component (gentisic acid) in a saturated solution of the 
more soluble component (piroxicam).  This was also done for the PSacc co-crystals. 
 
Table 3.4:  Piroxicam/gentisic acid co-crystal preliminary screening parameters. 
Co-
crystal 
Acid 
Concentration 
Piroxicam 
Added 
(mg) 
Solution 
Scale 
(mL) 
Recovery 
(mg) 
Yield 
(%) 
Piroxicam/Coformer 
Ratio by HPLC 
PGA #1 3.5 mg/mL 270 3 25 76 3:1 
PGA #2 3.5 mg/mL 135 2 11 50 2:1 
PGA #3 3.5 mg/mL 6600 75 752 91 1.6:1 
 
 
Optimizing the experimental parameters to give the best co-crystal yield was not the focus of this 
research and a large amount of unreacted piroxicam was discarded when the co-crystal solutions 
were filtered.  This large amount of API used was not an issue for this research.  This would 
most likely not be acceptable for a pre-development candidate where material may be limited.  
However, it is possible to adjust the experimental conditions of the reaction crystallization 
process to optimize co-crystal yield if needed.   
For some of the coformers that did not precipitate piroxicam co-crystals, solution 
complexation was observed.  This phenomenon was comprehensively studied in the 1950’s by 
Higuchi et. al. and demonstrated how the solubility of poorly water soluble drugs can increase 
via solution complexation with a more soluble ligand (or coformer).
5-7
  Piroxicam solubility 
doubled in saturated 1:1 and 2:1 THF/IPA solutions of malonic acid.  In saturated succinic acid 
trifluoroethanol solution, piroxicam solubility increased by 20 %.  The possibility of solution 
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complexation reveals the importance of generating solubility data for the API and coformers in 
the solvents chosen for co-crystal screening.  It also demonstrates the value of monitoring the 
solution concentration of the reactants during co-crystal screening in order to gain a better 
understanding of the reaction crystallization process. 
 
Conclusions 
 Based on the solubility data for piroxicam and nine carboxylic acids in a variety of 
solvents, experiments were carried out at room temperature using the reaction crystallization 
method that resulted in piroxicam co-crystals with six of the coformers.  This study was not 
meant to be an exhaustive co-crystal screen; therefore, it is possible that the three coformers that 
did not form piroxicam co-crystals might be successful using this method with other solvents 
and/or temperatures not explored in this research. 
 HPLC analysis of the piroxicam and coformer solution concentrations as well as any 
solid that precipitated out of the solution was helpful in determining whether the co-crystal 
synthesis was successful.  If the HPLC results suggested that the solid was a co-crystal, it was 
further characterized by XRPD, DSC, and TGA.   Monitoring the solution concentrations of the 
reactants was also useful because it helped identify any unexpected results such as solution 
complexation. 
The reaction crystallization method proved to have many advantages over co-crystal 
formation by slow evaporation because it produced pure co-crystals that were easily scalable.  
Furthermore, co-crystal formation could be visibly observed and the co-crystals often formed 
quickly in as little as a few minutes to a couple hours.   
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CHAPTER 4.  Co-crystal Solubility  
 
Purpose of the Research Performed  
The purpose of the research performed in this chapter was to measure the aqueous 
equilibrium solubility of the piroxicam co-crystals and predict co-crystal pH – solubility 
behavior. 
  
Introduction 
 As a BCS Class II compound, piroxicam oral absorption is solubility limited.  Co-crystals 
have been shown to improve drug solubility;
1, 2
 therefore, measuring co-crystal solubility is 
desirable in order to determine whether the co-crystal form is more soluble than the free form 
and thus have greater bioavailability.  Most co-crystal solubility measurements reported in the 
literature are kinetic solubility measurements of dissolution and not the true equilibrium 
solubility of the co-crystal form.
3, 4
  Often times during these experiments, the co-crystal will 
dissociate, in which case what is being measured is really the solubility of the free form of the 
API.  In fact, most relevant pharmaceutical co-crystals are more soluble than pure API and 
therefore are more prone to transformation when exposed to pure solvent.
1
  For co-crystals 
composed of ionizable compounds, solubility increases seen during kinetic measurements could 
be due to a pH-solubility effect caused by the acid/base properties of the coformer and/or API 
and not the overall solubility of the co-crystal. 
 Good and Rodríguez-Hornedo have developed methods to determine co-crystal 
equilibrium solubility that are experimentally accessible and reproducible.
1
  The dissociation of a 
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co-crystal in solution can be described by the solubility product (Ksp), which is defined as a 
product of drug and coformer solution concentrations.
5, 6
  For co-crystals that are stable or 
metastable when exposed to a pure solvent, the equilibrium co-crystal solubility (SCC) can be 
determined from a single measurement of solution in equilibrium with solid drug and co-crystal.
1
  
Furthermore, based on the Ksp measured in aqueous solution, the pH-solubility behavior of the 
co-crystal can be predicted.
7
   
 In this chapter, phase diagram experiments as described by Higuchi et. al.
8
 were 
conducted in trifluoroethanol to confirm the stoichiometry of the PBA co-crystal.  This work led 
to a better understanding of the theories behind co-crystal formation by reaction crystallization
6
 
and equilibrium co-crystal solubility measurements
1
.  These methods were applied to measure 
the equilibrium aqueous solubility of the piroxicam co-crystals.  The pH-dependent solubility of 
the co-crystals was also investigated. 
 
Experimental 
PBA Phase Diagram Experiments 
 Individual saturated solutions of benzoic acid in trifluoroethanol were made with the total 
volume and benzoic acid content the same (0.49 M) for each solution.  Increments of piroxicam 
ranging from 0 - 150 mg/mL were added to each solution.  The solutions were shaken for 24 
hours at room temperature.  After 24 hours, the solutions were filtered using a 0.45 µm 
polyvinylidene fluoride membrane and the benzoic acid and piroxicam solution concentrations 
were analyzed by HPLC.  
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Equilibrium Co-crystal Solubility 
Piroxicam co-crystal equilibrium solubilities in water were determined at room 
temperature by suspending excess co-crystal in HPLC grade water.  The solutions were shaken 
on an orbital shaker for approximately 24 hours.    Solutions were filtered using a 0.45 µm 
polyvinylidene fluoride membrane and analyzed by HPLC.  If necessary, samples were diluted in 
methanol prior to analysis.  The pH of the filtered solution was also measured.  Piroxicam 
solubility was also measured as a control.  The remaining solid phase was collected by vacuum 
filtration, dried at room temperature, and analyzed by XRPD to verify that the solid phase was 
the co-crystal.  Equations 1 and 2 were used to calculate the measured solubilities of the 1:1 
piroxicam/acid co-crystals.  The fraction of nonionized piroxicam (FP) and acid (FA) were 
calculated using the Henderson-Hasselbalch equation.  Equations 3 and 4 were used to predict 
co-crystal solubility at various pH values.  It is important to note that these equations assume 
ideal behavior with concentrations replacing activities in the equilibrium constants.   
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Piroxicam and Coformer Aqueous Solution Concentrations by HPLC 
Solution concentrations were determined using the HPLC experimental procedure 
described in Chapter 3.  
 
Results and Discussion 
 The results from the PBA phase diagram experiments can be seen in Figures 4.1 – 4.3.  
Figure 4.1 is a plot of the measured benzoic acid solution concentration at equilibrium versus the 
amount of piroxicam added.  Each data point represents an individual solution.  From the straight 
line portion of this plot (inset plot in Figure 4.1), the co-crystal stoichiometry was determined by 
calculating how much piroxicam and benzoic acid precipitated out of solution (initial 
acid/piroxicam concentration minus the solution concentration at equilibrium).   A 1:1 co-crystal 
will have the same molar amount for each component.  These results confirmed that the 
piroxicam / benzoic acid co-crystal stoichiometry was 1:1.   
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Figure 4.1:  Piroxicam / benzoic acid phase diagram. 
 
Following a suggestion from Professor Naír Rodríguez-Hornedo, a plot of the 
equilibrium solution concentrations of piroxicam versus benzoic acid (Figure 4.2) was made 
using the data points from the straight line portion in Figure 4.1.  From this plot the piroxicam 
and benzoic acid transition concentrations, [P]tr and [BA]tr, were identified where the two lines 
intersect and were used to determine the co-crystal solubility product, Ksp.  From the Ksp, co-
crystal solubility, SPBA, can be determined using Equations 5 and 6.
5
   
 
trtrsp BAPK ][][  (5) 
spPBA KS    (6) 
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Figure 4.2:  Piroxicam / benzoic acid solubility plot. 
 
PBA solubility can also be quantified from a plot of piroxicam concentration versus 
1/benzoic acid concentration (Figure 4.3).  This plot also gives the Ksp as well as the binding 
constant, K11, where the slope equals the Ksp and the intercept equals the K11Ksp.  Using these 
values, co-crystal solubility was calculated using Equation 7 which incorporates the binding 
constant, where [BA]T equals the total benzoic acid concentration (0.94 M).
5
   
PBA solubility determined from Figure 4.2 (using Equations 5 and 6) was 0.08 M.  The 
solubility value calculated from Figure 4.3 and Equation 7 was 0.09 M.  While these two plots 
yield similar solubility values, it demonstrates how co-crystal solubility can change by taking 
into account the binding constant.   It is worth mentioning that since these experiments were 
performed in trifluoroethanol, the transition concentrations and Ksp values determined from these 
[P]tr and [BA]tr 
and SPBA 
↓ 
1:1 
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experiments are only relevant to the solubility of PBA in trifluoroethanol and can not be used to 
calculate co-crystal solubility in other solvents. 
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Figure 4.3:  Piroxicam / Benzoic acid plot used to determine binding constant. 
 
 While co-crystal solubility can be determined from phase diagram experiments, this work 
is not necessary if co-crystal material is available.  A much simpler method is to make a 
saturated co-crystal solution (with excess co-crystal solid) in the solvent of interest, let it 
equilibrate, and measure the solution concentration of the drug and coformer (transition 
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concentrations).
1
  This method was used to determine the aqueous solubility of the piroxicam co-
crystals.   
 The measured solubilities of the piroxicam co-crystals in water at room temperature after 
24 hours are listed in Table 4.1 along with the final solution pH values.  Co-crystal solubility was 
dependent on the intrinsic solubility of the coformer (Table 4.1) and solution pH.  It was 
observed that the greater the coformer solubility, the greater the co-crystal solubility.  Coformers 
with higher aqueous solubility (benzoic acid, 4-hydroxy benzoic acid, and gentisic acid) resulted 
in piroxicam co-crystals with greater solubility than those made with coformers with lower 
solubility (salicylic acid and saccharin).  XRPD patterns of the solid phase after 24 hours 
confirmed that the remaining solid form was co-crystal and traces of piroxicam monohydrate 
(XPRD patterns can be found in the appendix).   The equilibrium aqueous solubility of PSucA 
could not be measured because the co-crystal components quickly dissociated when suspended in 
solution indicating that the co-crystal form was not thermodynamically stable in water.  This 
result is not unexpected given the high aqueous solubility of succinic acid relative to piroxicam 
(Table 4.1).  Co-crystal solubility has been shown to be dependent on the solubility of co-crystal 
components with coformer solubility about 10-fold higher than drug leading to a co-crystal that 
is more soluble than drug.
1
  Therefore, one could speculate that PSucA is more soluble than 
piroxicam.  This information is also useful for designing a co-crystal that is more soluble.   
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Table 4.1:  Coformer and co-crystal equilibrium solubility in water at room temperature. 
Co-crystal 
Coformer 
Solubility, mM  
(pH) 
Coformer 
pKa(s) 
Co-crystal 
Solubility (uM) 
n=3 
pH Ksp (M
2
) 
PBA 26 (2.8) 4.2 310 ± 4.28 3.3 9.60 x 10
-8
 
PSA 13 (2.5) 3.0 68.3 ± 2.83 3.5 4.66 x 10
-9
 
P4hBA 38 (3.0) 4.5, 9.3 275 ± 13.1 3.6 7.57 x 10
-8
 
PSacc 17 (1.8) 2.0 142 ± 2.27 2.5 2.03 x 10
-8
 
PGA 130 (1.9) 3.0 291 ± 1.50 2.7 8.49 x 10
-8
 
PSucA 620 (2.0) 4.2, 5.6 nd nd nd 
*nd = no data. 
 
The aqueous solubilities of the co-crystals were measured in unbuffered water; therefore, 
a change in pH was observed due to the dissociation of the acidic co-crystal components.  
Because solution pH was not controlled, the measured co-crystal solubilities could not be 
directly compared to piroxicam solubility alone (also measured in unbuffered water).  Equations 
have been derived to calculate and predict co-crystal solubility and stability in water based on 
solution pH, solubility product, and dissociation constant(s) of the co-crystal components.
7, 9
  
The Ksp calculated from experimentally measured co-crystal solubility at one pH can be used to 
predict co-crystal solubility at other pH values.  A saturated solution of piroxicam in water has a 
pH value of 6.9.  To compare to the measured piroxicam solubility (Table 4.2), the co-crystal 
solubilities were predicted at pH 6.9 (Table 4.2) using equations 3 or 4.  At pH 6.9, the co-crystal 
solubilities were predicted to be about 225 (4-hydroxy benzoic acid co-crystal) to 2000 times 
(saccharin co-crystal) more soluble than piroxicam.  An attempt was made to measure the 
equilibrium solubilities of the co-crystals at pH 6.9 to compare to the predicted values; however, 
this was not feasible because the solution pH could not be controlled independently.  Despite 
increases in buffer concentration, the solution pH was driven by the acid coformer concentration.  
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Furthermore, the co-crystals completely dissociated to piroxicam monohydrate and coformer.  In 
other words, the co-crystals were not thermodynamically stable at pH 6.9.    
 
Table 4.2  Co-crystal predicted solubility at pH 6.9. 
Compound Solubility (mM) 
Co-crystal/Piroxicam 
Solubility Ratio 
Piroxicam 0.16 -- 
PBA 55 344 
PSA 50 313 
P4hBA 36 225 
PSacc 320 2000 
PGA 220 1375 
 
 The pH-dependency of the solubility of pharmaceutical acids and bases has been well 
established.
10
  As a zwitterionic drug, piroxicam solubility is higher at pH values below its pKa1 
(1.8) and above its pKa2 (5.1).  In its neutral form, between pH 1.8 and 5.1, piroxicam has its 
lowest solubility. Since piroxicam solubility is affected by pH, piroxicam equilibrium solubility 
was measured at pH 2, 3, and 4 in order to compare to the equilibrium co-crystal solubilities 
(measured at pH 2.5 – 3.3).  The results can be seen in Figure 4.4.  With the exception of the 
PSA co-crystal, all co-crystals had a significant solubility advantage over piroxicam between pH 
2-4.  
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Figure 4.4:  Piroxicam pH-dependent solubility and measured co-crystal solubility, n=3. 
 
Conclusions 
 A method developed by Rodríguez-Hornedo et. al.
1, 5, 6
 to measure co-crystal equilibrium 
solubility was applied to determine piroxicam co-crystal solubility in water at room temperature.  
Further research builds on these principles and allows one to measure and predict co-crystal 
solubility and stability as a function of pH, 
7, 10
  These methods were applied to predict piroxicam 
co-crystal solubility at pH 6.9, a region in which the piroxicam co-crystals were not stable.  
Except for the PSA co-crystal at low pH, all co-crystals had a solubility advantage over 
piroxicam at pH 2 - 4 and 6.9.   
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Equilibrium solubility measurement and solubility prediction methods applied in this 
research are extremely useful because (1) they enable co-crystal solubility and pH dependent 
solubility to be measured and predicted from a single experiment using very little material 
(approximately 30 – 50 mg in this study) and (2) they allow co-crystal solubility to be predicted 
in pH regions where the co-crystal and/or co-crystal components are not stable.
10
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CHAPTER 5.  Co-crystal Intrinsic Dissolution and Rat Pharmacokinetics 
 
 
Purpose of the Research Performed  
The purpose of the research performed in this chapter was to measure the dissolution 
rates of the piroxicam co-crystals at physiological pH, to determine co-crystal in-vivo 
bioavailability, and to establish possible correlations between dissolution and pharmacokinetic 
data. 
 
Introduction 
 Dissolution testing is used by formulation scientists to assist in choosing among drug 
candidate solid state forms and formulations as well as to establish possible in vivo / in vitro 
correlations between release of the drug from the dosage form and drug absorption.
1, 2 
  
Evaluation of dissolution profiles is especially important for Class II drugs since dissolution for 
these substances is assumed to be rate limiting step to in vivo absorption.
3, 4
   
 Intrinsic dissolution studies are often carried out using a Woods Apparatus comprised of 
rotating disks of compacted powder of the API immersed in dissolution test media.
5
  This 
method affords advantages over powder dissolution methods because the exposed area of the 
disk is constant and thus dissolution variability from particle size is eliminated during the 
dissolution period.   
The solubility advantage of co-crystals has been shown to correlate with increased 
dissolution and bioavailability.
6-8
  Piroxicam co-crystal solubility was significantly greater than 
piroxicam.  Therefore, in order to assess whether this solubility advantage correlates with 
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increased dissolution and oral exposure, intrinsic dissolution profiles for the co-crystals were 
generated in biorelevant media at pH 1.2 and 6.8.  The effect of buffer concentration on co-
crystal dissolution rate was also evaluated.  Finally, co-crystals were dosed orally in rat to 
determine co-crystal bioavailability and draw correlations, if any, between the in vivo results and 
in vitro dissolution data.   
 
Experimental 
Instrinsic Dissolution 
A miniature Wood’s Apparatus (Distek 2100C, North Brunswik, NJ) was used to 
measure the dissolution rate of the co-crystals in US Pharmacopeia buffers at pH 1.2 (0.07 M 
HCl/ 0.03 M NaCl) and 6.8 (0.05 M monobasic potassium phosphate/0.03 M NaOH).
9
  
Dissolution rates were also measured in 0.1 M monobasic potassium phosphate at pH 6.8.  
Approximately 10 - 15 mg of co-crystal was compressed in a punch die at 400 psi for one 
minute.  All dissolution studies were preformed in 100 mL of solution at 37°C.  Paddle rotation 
speed was 100 rpm.  Time points were collected for up to 2 hours and piroxicam concentrations 
were analyzed by HPLC (see Chapter 3 experimental for HPLC method).  Piroxicam dissolution 
rates were calculated by plotting the cumulative amount of piroxicam dissolved per unit area 
(Equation 8) versus time.  The piroxicam reference standard dissolution profile was also 
determined as a control.  Bulk solution pH was measured at the end of the experiments and the 
left over pellet was analyzed by XRPD to verify that the solid state of each co-crystal was the 
same as the starting material.   
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Rat Pharmacokinetics 
Adult male Sprague Dawley (Charles River, Kingston, New York) rats were used in all 
experiments.  The rats were fasted overnight prior to oral dose administration.  Intravenous 
administration was via the lateral tail vein and oral doses were administered by gavage.  
Piroxicam and piroxicam co-crystals were orally dosed in capsules at 5 mg/kg piroxicam 
equivalents.  Piroxicam was also dosed intravenously at 1 mg/kg in DMSO/Solutol®/PBS 
(3/30/67) in order to calculate bioavailability.  For blood collection, each rat (unanesthetized) 
was placed in a clear Plexiglas
®
 restraining tube and blood samples (approximately 0.25 mL) 
were drawn from a lateral tail vein into heparinized collection tubes.  Blood samples were 
collected out to six hours.  The blood samples were placed on wet ice until centrifuged to 
separate plasma.  The plasma fraction was transferred into clean dry tubes, frozen on dry ice and 
stored at approximately -20
o
C pending analysis.   
Piroxicam plasma concentration was determined by LC/MS/MS (an integrated Cohesive 
Technologies LX-2 series liquid chromatography system coupled with an Applied Biosystems 
MDS-SCIEX 4000 Qtrap mass spectrometer, Foster City, CA).  Plasma proteins were 
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precipitated with acetonitrile containing an internal standard (alprenolol).  Calibration standards 
were prepared in rat plasma ranging from 10 – 10000 ng/mL.  WinNonLin® was used to 
calculate pharmacokinetic parameters.   
Statistics 
A one-way analysis of variance (ANOVA) test was performed to demonstrate statistical 
significance.  p < 0.05 was considered statistically significant. 
 
Results and Discussion 
 
Intrinsic Dissolution 
The dissolution profiles for piroxicam and the co-crystals at pH 6.8 and at pH 1.2 are 
shown in Figures 5.1-5.5.  Dissolution rates were determined from the slopes of the linear 
regression lines and are listed in Table 5.1.  The piroxicam reference standard dissolution rates 
measured were in agreement with previous reports.
2
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Figure 5.1:  Piroxicam and co-crystal dissolution profiles in 0.05 M phosphate buffer, pH 6.8. 
 
Dissolution at pH 6.8.  At pH 6.8, all co-crystals had significantly lower dissolution rates 
than piroxicam alone (Table 5.1).  These results are most likely due to a drop in pH occurring at 
the solid-liquid interface.  The interfacial pH is affected by the degree of dissociation of the acid 
or base at the interface, which is determined by the concentration and pKa of the acid.
10
  As the 
acid coformer dissociates, hydrogen ions are released thus lowering the pH of the diffusion layer 
relative to that of the bulk solution.  Since piroxicam at pH 6.8 is acidic, the lower interfacial pH 
suppresses the solubility and thus dissolution rate.  The pH 6.8 dissolution data illustrates that a 
co-crystal will quickly dissociate during dissolution experiments performed in pH regions where 
the drug and coformer are ionized.  Once the co-crystal dissociates, the dissolution rate is driven 
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by the intrinsic solubility of the drug as function of pH.
10
  These results reveal the importance of 
understanding the acid/base properties of both drug and coformer and how they can impact the 
overall dissolution rate of the drug.  Furthermore, it emphasizes the need to stabilize the co-
crystal to prevent dissociation and achieve the solubility and dissolution advantages of the co-
crystal form
11
.   
 
Table 5.1:  Piroxicam dissolution rates at pH 1.2 and 6.8 at 37°C (µg/min/cm2). 
Compound pH 1.2
a 
pH 6.8 (0.05M)
b 
Piroxicam 54 ± 7.0 130 ± 17 
PBA 62 ± 7.5 32 ± 1.5 
PSA 48 ± 18 34 ± 2.1 
P4hBA 66 ± 5.1 33 ± 3.2 
PSacc 42 ± 12 59 ± 11 
PGA 40 ± 3.6 46 ± 2.1 
PSucA 25 ± 7.9 31 ± 5.0 
a
 30 minute dissolution rate. 
b 
2 hour dissolution rate. 
 
Previous research has shown that dissolution behavior can be affected by buffer 
concentration.
12
  Therefore, in an attempt to dampen pH changes within the diffusion layer, 
potassium phosphate buffer concentration was doubled to 0.1 M.  The dissolution profiles are 
shown in Figure 5.2.  While the dissolution rates of the co-crystals were still significantly lower 
than piroxicam alone, the increased buffer concentration appeared to give a small boost to the 
dissolution rates (Figure 5.3), which was significant for the PBA and PSA co-crystals.  The 
pKa(s) and intrinsic solubility of the acid as well as the pKa of the buffer are important to take 
into account when interpreting the dissolution data; therefore, the equilibrium solubilities of 
piroxicam and the acids were measured in the dissolution media and are listed along with their 
pKa(s) in Table 5.2.  Solubility in 0.1 M potassium phosphate buffer was not determined due to 
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limited material for some of the acids but one would expect the solubility to be comparable to 
0.05 M.  The PSucA co-crystal dissolution rate in these buffer conditions was not determined 
because based on the results for the other co-crystals, it was concluded that the dissolution 
behavior of PSucA would be similar.   
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Figure 5.2:  Piroxicam and co-crystal dissolution profiles in 0.1 M phosphate buffer, pH 6.8. 
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Figure 5.3:  Dissolution rate comparison in 0.05 M and 0.1 M buffer, pH 6.8. 
 
Table 5.2:  Piroxicam and coformer solubility in biorelevant media (mM). 
Compound pH 1.2 pH 6.8 (0.05M) pKa(s) 
Piroxicam 0.36 1.20 1.8, 5.1 
Gentisic Acid* 118.43 129.76 3.0 
4-hydroxy Benzoic Acid 54.75 85.64 4.5, 9.3 
Salicylic Acid 13.88 48.25 3.0 
Saccharin 9.93 59.33 2.0 
Benzoic Acid 42.78 67.23 4.2 
*Solution not completely saturated due to limited material. 
 
No significant changes in piroxicam dissolution rate were observed for the PGA and 
P4hBA co-crystals with an increase in buffer concentration.  This can be explained by 
dissolution rate dependency on the intrinsic solubility of the acids and pH.  Acids with higher 
solubilities, i.e. gentisic acid and 4-hydroxy benzoic acid, are less sensitive to buffer 
concentration and pH because they are so soluble that they “self-buffer” the pH in the diffusion 
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layer.
12  
In other words, high concentrations of hydrogen ions are released in solution from these 
acids which consume all the unprotonated form of the buffer.  Benzoic acid and salicylic acid 
have lower solubilities and therefore are less able to self-buffer the diffusion layer pH.  The co-
crystals with these acid coformers (PBA and PSA) have piroxicam dissolution rates that are 
affected more by an increase in buffer concentration.  
Dissolution at pH 1.2.  Dissolution experiments were also conducted at pH 1.2.  The 
results are shown in Figure 5.3.  After 45 minutes, there was a great deal of variability between 
the three pellets for each co-crystal so it was difficult to draw conclusions for the complete two 
hour dissolution period; however, differences were observed within the first 30 minutes (Figure 
5.4).  In the first 30 minutes for the PBA and P4hBA co-crystals, the cumulative amount of 
piroxicam dissolved per unit area for each individual time point was significantly greater than 
piroxicam (Figure 5.5).  The piroxicam dissolution rate for these co-crystals (Table 5.1) also 
appeared to be slightly improved; however, it was not statistically different at the 95% 
confidence interval (PBA, p = 0.2 and P4hBA, p = 0.07).   
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Figure 5.3:  Piroxicam and co-crystal 2 hour dissolution profiles at pH 1.2. 
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Figure 5.4:  Piroxicam and co-crystal 30 minute dissolution profiles at pH 1.2. 
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Figure 5.5:  Piroxicam, PBA, and P4hBA 30 minute dissolution profiles at pH 1.2 
 
The dissolution results at pH 1.2 can be explained by examining the solubility and pKa of 
the acid coformers.  Benzoic acid and 4-hydroxy benzoic acid have pKa values over four and in a 
solution at pH 1.2, all the acid species should be in the unionized form.  Saccharin, gentisic acid, 
and salicylic acid, however, have lower pKa values around 2 - 3 which are much closer to pH 
1.2.  It is possible that there was a small percentage of these acids in the ionized form.  As 
previously stated, dissociation of the acid liberates hydrogen ions and therefore lowers the pH of 
the diffusion layer relative to the bulk solution pH.  The intrinsic solubilities of the acids also 
contribute to dissolution rate.  Benzoic acid and 4-hydroxy benzoic acid were about five times 
more soluble than salicylic acid and saccharin in the dissolution media.  Gentisic acid and 
succinic acid were the most soluble of all the acid coformers; however, the gentisic acid and 
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succinic acid co-crystals did not significantly boost the piroxicam dissolution rate.  This could be 
explained if there were some fraction of the acid dissociating that changes the pH of the diffusion 
layer and thus the dissolution rate.   
 
Pharmacokinetics  
Solubility is one of the many physiochemical factors that affect oral absorption of a 
drug.
13
  As a Class II drug (high permeability, low solubility), the in vivo absorption rate of 
piroxicam is limited by its low solubility.
14
  Therefore, based on the co-crystal solubility results, 
one might expect the co-crystals to have higher bioavailability.  The oral exposure profiles and 
calculated six hour rat bioavailability for piroxicam and the co-crystals can be seen in Figure 5.6 
and Table 5.3.  Statistical analysis (ANOVA, p>0.05) revealed that co-crystal bioavailability was 
not different than piroxicam.  Additional pharmacokinetic data not listed in this chapter can be 
found in the appendix.     
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Figure 5.6:  Piroxicam 6 hour rat plasma levels after oral capsule dosing (n=3). 
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Table 5.3:  Piroxicam and co-crystal 6 hour bioavailability (n=3). 
Compound Bioavailability (%) ± sem 
Piroxicam Reference Standard 30 ± 2 
PBA 31 ± 5 
PSA 34 ± 1 
PGA 44 ± 7 
P4hBA 38 ± 3 
PSacc 44 ± 9 
PSucA 40 ± 6 
 
The gentisic acid and saccharin co-crystals appeared to possibly give a slight boost to 
piroxicam plasma levels within the first hour.  Therefore, a one hour PK study with additional 
time points was conducted for piroxicam and the gentisic acid and saccharin co-crystals to 
confirm these results.  These results are shown in Figure 5.7.  No significant differences were 
observed compared to piroxicam for the saccharin co-crystal.  Piroxicam exposure from the 
gentisic acid co-crystal appeared to be greater within the first 30 minutes but was not 
significantly different (p=0.3).    
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Figure 5.7:  Piroxicam 1 hour rat plasma levels after oral capsule dosing (n=6). 
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Overall the pharmacokinetic data was variable and no significant differences were 
observed between the co-crystals and piroxicam.  It is likely that the co-crystals quickly 
dissociated as the capsules dissolved in the stomach.  Improved oral exposure has been reported 
for co-crystals that have been formulated to stabilize the co-crystal form.
15
  It is possible that 
stabilizing the piroxicam co-crystals with a  formulation could result in increased oral exposure.  
 
Conclusions 
Piroxicam dissolution rates appeared to be most dependent on interfacial pH, which was 
driven by the intrinsic solubility and dissociation constant(s) of the coformer.  This effect was 
most apparent at pH 6.8 with piroxicam co-crystal dissolution rates significantly lower than 
piroxicam alone.  At pH 1.2, piroxicam co-crystal dissolution rates were similar to free 
piroxicam.  In this pH region ionization of the co-crystal components was negligible so as the co-
crystal dissociates, one would expect the piroxicam dissolution rate from the co-crystals to be 
similar to free piroxicam. 
Overall, the in vivo data correlated well with the in vitro intrinsic dissolution results at pH 
1.2.  This is not unexpected given that the capsules were dosed directly into the stomach, which 
has a presumed pH of 1 - 2.  Physiological factors including the site of absorption, 
gastrointestinal blood flow, and gastric emptying also play an important role in oral absorption.  
These variables make it difficult to completely understand the absorption processes occurring in 
vivo for the co-crystals.  Furthermore, it is probable that the co-crystals quickly dissociated in 
vivo which would hinder any potential increases in bioavailability from the co-crystal form.  In 
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future studies formulation strategies to stabilize a co-crystal should be studied in order to fully 
utilize the solubility advantage of co-crystals.   
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CHAPTER 6.  Final Conclusions and Future Considerations 
 
In this thesis, co-crystal methodology and behavior was explored to better understand co-
crystal technology and assess the feasibility of creating co-crystals in an early development 
setting to address API solubility issues.  Slow evaporation methods to create co-crystals on a 
large scale were quickly abandoned because the method proved to be too time consuming and 
often produced a mixture of products and not pure co-crystal.  However, slow evaporation 
methods are still useful for discovering new co-crystal forms on a small scale.   
Reaction crystallization proved to the method of choice for this project to produce 
scalable batches of pure co-crystals.  Using this method, co-crystal formation could be visibly 
observed and co-crystals often formed very quickly.  The reaction process was also easily 
controlled and the results were reproducible for small and large batches of co-crystals.  It was 
discovered that co-crystal yield could be optimized while conserving API and coformer material 
by suspending the least soluble component in a saturated solution of the more soluble 
component.  
Equilibrium co-crystal solubility measurement techniques developed by Nair Rodríguez-
Hornedo and colleagues were successfully applied to measure co-crystal solubility.  Measuring 
co-crystal equilibrium solubility is very useful as a means to screen for a co-crystal that is more 
soluble than the API.  Additionally, this information can be used to estimate co-crystal 
solubilities in pH regions where the co-crystal may not be stable.  It is also valuable knowledge 
that can be used to both formulate the co-crystal and/or assess whether it is necessary to stabilize 
the co-crystal through formulation techniques.   
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 The intrinsic dissolution results for the piroxicam co-crystals demonstrated the need to 
understand the pH solubility and stability of the co-crystal and the co-crystal components and 
how this data will affect the overall dissolution rate of the API.  Any rapid dissociation of the co-
crystal is likely to reduce the solubility advantage and may cause suppression of the dissolution 
of the API due to the acid/base properties of the co-crystal components.  Both intrinsic 
dissolution and PK results reiterate the fact that the piroxicam co-crystals created herein will 
dissociate within targeted in vivo pH regions; therefore, formulation work is likely required to 
stabilize these co-crystals in order to achieve an increase in bioavailability.     
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CHAPTER 7.  Appendix 
 
 
Slow Evaporation Solid State Data 
 
 
 
Figure 7.1:  XRPD patterns for 1:1 piroxicam/malonic acid and starting materials. 
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Figure 7.2:  XRPD patterns for 2:1 piroxicam/malonic acid and starting materials. 
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Figure 7.3:  1:1 and 2:1 piroxicam/malonic acid XRPD comparison. 
 
2Theta (°) 
Intensity (counts) 
5 10 15 20 25 30 35 
0 
40000 
160000 
360000 
640000 
1000000 
1:1 and 2:1 Piroxicam/Malonic Acid Comparison 
2:1 500mg Scale 
2:1 2g Scale 
2:1 1g Scale 
1:1 500mg Scale 
1:1 50mg Scale 
1:1 2g Scale 
68 
 
 
Figure 7.4:  2:1 piroxicam/malonic acid DSC thermograms. 
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Figure 7.5:  1:1 piroxicam/malonic acid DSC thermograms (50 and 500 mg scales). 
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Figure 7.6:  1:1 piroxicam/malonic acid DSC thermogram (1 gram scale). 
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Figure 7.7:  XRPD patterns for 1:1 piroxicam/4-hydroxy benzoic acid and physical  
                            mixture. 
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Figure 7.8:  XRPD patterns for 1:1 piroxicam/4-hydroxy benzoic acid and starting  
                            materials. 
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Figure 7.9:  1:1 piroxicam/4-hydroxy benzoic acid DSC thermograms. 
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 Figure 7.10:  1:1 and 2:1 piroxicam/succinic acid XRPD pattern comparison. 
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Figure 7.11:  XRPD patterns for 2:1 piroxicam/succinic acid and starting materials. 
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Figure 7.12:  XRPD patterns for 1:1 piroxicam/succinic acid and starting materials. 
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Figure 7.13:  1:1 piroxicam/succinic acid DSC thermograms. 
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Figure 7.14:  2:1 piroxicam/succinic acid DSC thermograms. 
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Figure 7.15:  XRPD patterns for 1:1 piroxicam/benzoic acid and starting materials. 
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Figure 7.16:  XRPD patterns for 1:1 piroxicam/benzoic acid and physical mixture. 
 
Intensity (counts) 
5 10 15 20 25 30 35 
2Theta (°) 
0 
250000 
1000000 
2250000 
1:1 Piroxicam/Benzoic Acid 
500mg Scale 
50mg Scale 
2g Scale  
Physical Mixture 
81 
 
 
Figure 7.17:  1:1 piroxicam/benzoic acid DSC thermograms (50 mg and 2 g scales). 
50 mg scale 
2 g scale 
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Figure 7.18:  1:1 piroxicam/benzoic acid DSC thermograms (500 mg scale). 
 
 
 
 
 
 
 
 
1:1 Piroxicam / Benzoic Acid 500 mg scale 
83 
 
Reaction Crystallization Solid State Data 
 
 
Figure 7.19:  2:1 piroxicam/succinic acid co-crystal DSC thermogram (2:1 THF/IPA 
                 solvent). 
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 Figure 7.20:  2:1 piroxicam/succinic acid co-crystal DSC thermogram (1:1 THF/IPA 
                       solvent). 
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Figure 7.21:  XRPD patterns for 2:1 piroxicam/succinic acid co-crystals made with 1:1 and  
                       2:1 THF/IPA solvents. 
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Figure 7.22:  1:1 piroxicam/saccharin co-crystal DSC thermogram. 
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Figure 7.23:  1:1 piroxicam/gentisic acid co-crystal DSC thermogram. 
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Figure 7.24:  1:1 piroxicam/salicylic acid co-crystal DSC thermogram and TGA                   
                       overlay. 
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Figure 7.25:  1:1 piroxicam/benzoic acid co-crystal DSC thermogram and TGA                   
                       overlay. 
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Figure 7.26:  1:1 piroxicam/benzoic acid co-crystal XRPD pattern comparison with     
                       Childs reference co-crystal. 
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Figure 7.27:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal DSC thermogram and  
                      TGA overlay. 
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Figure 7.28:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal XRPD pattern  
                       comparison with Childs reference co-crystal. 
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Co-crystal Solubility XRPD Patterns 
 
 
Figure 7.29:  1:1 piroxicam/gentisic acid co-crystal XRPD pattern  
                       after aqueous solubility experiments. 
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Figure 7.30:  1:1 piroxicam/salicylic acid co-crystal XRPD pattern  
                                   after aqueous solubility experiments. 
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Figure 7.31:  1:1 piroxicam/benzoic acid co-crystal XRPD pattern  
                                   after aqueous solubility experiments. 
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Figure 7.32:  1:1 piroxicam/saccharin co-crystal XRPD pattern  
                                   after aqueous solubility experiments. 
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 Figure 7.33:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal XRPD pattern 
                        after aqueous solubility experiments. 
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Figure 7.34:  1:1 piroxicam/succinic acid co-crystal XRPD pattern after 
                            aqueous solubility experiments. 
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Co-crystal Intrinsic Dissolution XRPD Patterns 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.35:  1:1 piroxicam/benzoic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.05M buffer, pH 6.8). 
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Figure 7.36:  1:1 piroxicam/gentisic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.05M buffer, pH 6.8). 
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Figure 7.37:  1:1 piroxicam/saccharin co-crystal XRPD pattern after 
                               intrinsic dissolution experiments (0.05M buffer, pH 6.8). 
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Figure 7.38:  1:1 piroxicam/salicylic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.05M buffer, pH 6.8). 
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Figure 7.39:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal XRPD pattern after 
                   intrinsic dissolution experiments (0.05M buffer, pH 6.8). 
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 Figure 7.40:  Piroxicam reference standard XRPD pattern after intrinsic  
                                 dissolution experiments (0.05M buffer, pH 6.8). 
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Figure 7.41:  2:1 piroxicam/succinic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.42:  Piroxicam reference standard XRPD pattern after intrinsic  
                           dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.43:  1:1 piroxicam/saccharin co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.44:  1:1 piroxicam/benzoic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.45:  1:1 piroxicam/gentisic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.46:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal XRPD pattern after 
                   intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.47:  1:1 piroxicam/salicylic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (0.1M buffer, pH 6.8). 
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Figure 7.48:  Piroxicam reference standard XRPD pattern after intrinsic 
                            dissolution experiments (pH 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 10 15 20 25 30 35 
0 
2500 
10000 
22500 
Piroxicam uIDR, pH = 1.2 
Piroxicam Starting Material 
Piroxicam uIDR pellet 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.49:  1:1 piroxicam/saccharin co-crystal XRPD pattern after 
                              intrinsic dissolution experiments (pH 1.2). 
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Figure 7.50:  1:1 piroxicam/gentisic acid co-crystal XRPD pattern after 
                            intrinsic dissolution experiments (pH 1.2). 
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Figure 7.51:  1:1 piroxicam/benzoic acid co-crystal XRPD pattern after 
                                        intrinsic dissolution experiments (pH 1.2). 
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Figure 7.52:  1:1 piroxicam/4-hydroxy benzoic acid co-crystal XRPD pattern after 
                               intrinsic dissolution experiments (pH 1.2). 
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Figure 7.53:  2:1 piroxicam/succinic acid co-crystal XRPD pattern after 
                                        intrinsic dissolution experiments (pH 1.2). 
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Figure 7.54:  1:1 piroxicam/salicylic acid co-crystal XRPD pattern after 
                                        intrinsic dissolution experiments (pH 1.2). 
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Pharmacokinetic Data 
 
10
100
1000
10000
100000
0 1 2 3 4 5 6 7
n
g
/m
L
Time (h)
Plasma Levels of Piroxicam in Rat
1 mg/kg i.v., 5 mg/kg p.o. Capsules
Piroxicam Ref. Std. i.v.
Piroxicam Ref. Std. p.o.
 
Figure 7.55:  Piroxicam six hour plasma levels after intravenous and oral dosing. 
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Piroxicam Ref. Std. Rat 1 Rat 2 Rat 3 Mean stdev sem
t1/2, h #DIV/0! #DIV/0! #DIV/0!
AUC0-t, ng*h/mL 19998 18887 20105 19662 675 389
AUC0-, ng*h/mL #DIV/0! #DIV/0! #DIV/0!
Vd, L/kg #DIV/0! #DIV/0! #DIV/0!
CL, mL/min/kg #DIV/0! #DIV/0! #DIV/0!
1 mg/kg i.v.
Piroxicam Ref. Std. Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 10880 9010 11745 10545 1398 808
tmax, h 6.0 6.0 6.0 6.0 0.0 0.0
AUC0-t, ng*h/mL 30384 24684 32659 29242 4108 2375
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 31 25 33 30 4 2
5 mg/kg p.o. Capsules
PBA Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 7029 9408 12032 9490 2502 1447
tmax, h 4.0 6.0 6.0 5.3 1.2 0.7
AUC0-t, ng*h/mL 24602 25942 40742 30429 8956 5177
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 25 26 41 31 9 5
5 mg/kg p.o. Capsules
PSA Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 8669 11088 9875 9877 1210 699
tmax, h 6.0 6.0 6.0 6.0 0.0 0.0
AUC0-t, ng*h/mL 35080 31911 32508 33166 1684 973
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 36 32 33 34 2 1
5 mg/kg p.o. Capsules  
Figure 7.56:  Piroxicam and co-crystal six hour calculated  
pharmacokinetic parameters after intravenous or oral dosing. 
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PGA Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 10488 12000 10545 11011 857 495
tmax, h 6.0 6.0 4.0 5.3 1.2 0.7
AUC0-t, ng*h/mL 30915 45344 54122 43460 11717 6773
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 31 46 55 44 12 7
5 mg/kg p.o. Capsules
P4hBA Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 10710 10622 10507 10613 102 59
tmax, h 4.0 6.0 6.0 5.3 1.2 0.7
AUC0-t, ng*h/mL 42074 32763 36451 37096 4689 2710
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 43 33 37 38 5 3
5 mg/kg p.o. Capsules
PSacc Rat 1 Rat 2 Rat 3 Mean stdev sem
Cmax, ng/mL 8722.00 11659 11770 10717 1729 999
tmax, h 6.0 6.0 6.0 6.0 0.0 0.0
AUC0-t, ng*h/mL 25465 56624 46711 42933 15919 9202
AUC0-, ng*h/mL ND ND ND ND - -
t1/2, h ND ND ND ND - -
Oral Bioavailability %, 6h 26 58 48 44 16 9
5 mg/kg p.o. Capsules
PSucA Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean stdev sem
Cmax, ng/mL 10853 15080 8947 9483 15434 7585 11230 3292 1349
tmax, h 6.0 6.0 6.0 6.0 6.0 6.0 6.0 0.0 0.0
AUC0-t, ng*h/mL 36705 60448 41923 36533 45161 17364 39689 14022 5747
AUC0-¥, ng*h/mL ND ND ND ND ND ND ND
t1/2, h ND ND ND ND ND ND ND
Oral Bioavailability %, 6h 37 61 43 37 46 18 40 14 6
5 mg/kg p.o. Capsules  
 
Figure 7.57:  Co-crystal six hour calculated pharmacokinetic  
parameters after intravenous or oral dosing. 
 
 
Co-Crystal ng*h/mL sem
Piroxicam Ref. Std. 2115 707
PGA 2192 550
PSacc 1850 294
AUC ( 0 - 1h )
 
 
Figure 7.58:  Piroxicam and co-crystal calculated one hour AUC after oral dosing. 
 
 
